Skip to main content
. Author manuscript; available in PMC: 2018 Nov 29.
Published in final edited form as: Ann Oncol. 2018 Jan 1;29(1):145–153. doi: 10.1093/annonc/mdx483

Figure 1.

Figure 1

PlasmaDNA AI study of sequential plasma DNA sampling during first line aromatase inhibitor therapy for advanced breast cancer. (A) Consort diagram of plasma samples analysed for ESR1 mutations on the plasmaDNA AI study. (B) Baseline characteristics of patients in the PlasmaDNA AI study.